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ardiac hypertrophy is an independent risk factor for death largely because chronically hypertrophied hearts remodel and dilate, progressing from a stable compensation to dilated cardiomyopathy. 1 A better understanding of the mechanisms for functional decompensation of cardiac hypertrophy in response to hemodynamic overload is essential to develop effective preventative measures and therapeutics. A number of candidate pathological events have been identified, including bioenergetically unfavorable changes in contractile protein isoforms, 2 the metabolically adverse transition from fatty acid to glucose utilization, 3, 4 degradation of the cardiac matrix and resulting myocyte slippage, 5 and a relative decrease in myocardial vascularization resulting in oxidative stress. 6 Each of these factors becomes an additional physiological stressor for hemodynamically overloaded cardiomyocytes and in combination with the primary stimulus can ultimately overwhelm protective cell survival pathways 5 and result in apoptotic cardiomyocyte dropout with replacement fibrosis. Apoptotic loss of myocardium itself can increase hemodynamic stress through ventricular dilation and wall thinning and is therefore hypothesized to play an important role in the downward functional spiral that ultimately leads to overt heart failure. 5, 7 Although cardiomyocyte apoptosis is commonly observed in pressure overload hypertrophy [7] [8] [9] [10] and causes myocardial disease in experimental models wherein it was artificially induced, [11] [12] [13] [14] [15] the degree to which it contributes to ventricular remodeling in naturally occurring hypertrophy decompensation remains unclear. It is also not known whether cardiac myocytes that are programmed to die in pressure overload hypertrophy may nevertheless die a necrotic death if apoptosis is prevented, in which case inhibiting apoptosis would likely prove ineffective in preventing decompensation.
Editorial p 338 Clinical Perspective p 404
One approach to testing the hypothesis that apoptosis is a critical pathophysiological nodal point for multiple factors that induce hypertrophy decompensation, as well as for testing the therapeutic efficacy of apoptosis prevention to interrupt the feed-forward cycle of functional deterioration of pressure overload hypertrophy, is pharmacological caspase inhibition. 16 This approach is limited, however, by potential toxicity and lack of absolute specificity of these compounds, and it has not been reported in pressure overload hypertrophy. We considered that a more selective tactic of identifying proapoptotic factor(s) responsible for apoptosis after cardiac pressure overloading and individually manipulating them in the heart could better validate the hypothesis. Previously, we used DNA microarray analysis to identify Nix as a candidate hypertrophy-stimulated proapoptotic factor. 17 Nix is a nearly ubiquitous member of the Bcl2 family of mitochondrial-localized proteins that is expressed at very low levels in normal hearts but was strikingly upregulated in cardiacspecific Gq-overexpressing mice, a genetic model that recapitulates the molecular pathways and essential features of pressure overload hypertrophy. 18, 19 Nix provokes apoptosis in transfected cells and acts synergistically with normal maturational growth to cause apoptotic heart failure in neonatal mice, but its overexpression alone was not sufficient to cause apoptotic cardiac decompensation in normal adult hearts. 13, 15 It is not known whether Nix is essential for apoptosis that occurs in Gqmediated or pressure overload hypertrophy and therefore represents a specific, targetable apoptotic effector of hypertrophy decompensation. To test this, we used cardiac-specific conditional Nix gain-and loss-of-function mouse models in combination with genetic and physiological stress. Our results support a critical role for Nix in remodeling of hemodynamically overloaded hearts and more clearly define the consequences of cardiomyocyte apoptosis in functional decompensation after pressure overload hypertrophy.
Methods

Generation and Characterization of Genetically Modeled Mice
Mice with cardiac-specific Gq overexpression or inducible, attenuated expression of Nix were described previously 13, 18 and were interbred. Gq transgenic mice were mated with Nix null mice 20 for peripartum cardiomyopathy studies.
To produce cardiac Nix del animals, mice homozygous for floxed Nix alleles (Nix f/f ) 20 were mated with Nkx-Cre knockin mice. 21 Nix f/f mice were used as wild-type (WT) controls. Mice were housed and studied according to procedures approved by the University of Cincinnati Institutional Animal Care and Use Committee. Two-dimensional directed M-mode echocardiography, histopathology, and terminal deoxynucleotidyl transferase-mediated dUTP biotin nick end labeling (TUNEL) studies were performed as described previously. 13 
Expression Analysis With Quantitative Polymerase Chain Reaction
One microgram of total RNA purified from snap-frozen mouse hearts with the use of Trizol (Invitrogen, Carlsbad, Calif) was reverse-transcribed with the use of oligo(dT). Amplicons spanning exons 2 to 4 of Nix (Bnip3L, GenBank NM_009761, nucleotides 298 to 414) were detected with the use of SYBR Green I during 35 cycles of quantitative polymerase chain reaction (95°C for 15 seconds, 60°C for 1 minute) with the use of 5Ј-AAGAGGCAGTTCGCA-CTGTGACA-3Ј (forward) and 5Ј-TCTACAACTTCTTCTTCT-GACTGAGAGCTG-3Ј (reverse) primers. TaqMan assays for atrial natriuretic factor, SERCA2a, ␣-skeletal actin, and GAPDH were purchased from Applied Biosystems (Foster City, Calif).
Studies With Pressure Overload Modeling
Twelve-week-old mice underwent acute pressure overloading by surgical transverse aortic constriction (TAC). 19 Periprocedural mortality was Ϸ25% in both groups. Cardiac magnetic resonance imaging studies were performed as described. 22 Terminal invasive studies for assessment of transcoarctation gradient and left ventricular (LV) hemodynamics were performed as described previously. 19 
Myocardial Histomorphometric Analysis
Myocyte cross-sectional area was determined with the use of FITC-tagged wheat germ agglutinin labeling. 23 TUNEL staining used the DeadEnd fluorometric TUNEL system (Promega, Wis) counterstained with ␣-sarcomeric actin (Invitrogen) and DAPI (Vector Laboratories, Burlingame, Calif) and imaged with the use of a UV transparent ϫ100 oil immersion objective. Only TUNELpositive nuclei within sarcomeric actin-stained cardiomyocytes were counted. Cleaved caspase-3 and poly(ADP-ribose) polymerase (PARP) were analyzed as described. 24 Masson's trichrome-stained myocardial sections were imaged (ϫ200), and collagen area was calculated as percentage of total LV myocardial area with the use of NIH Image software.
Statistical Analysis
Results are meanϮSEM. Experimental groups were compared with the use of Student t test for comparison between 2 groups, 1-way ANOVA for comparing multiple groups, or 2-way repeated-measures ANOVA for time-dependent changes between various groups, followed by the Tukey post hoc test. Nonparametric testing was employed when data were not normally distributed. The Dunn post hoc test was employed after ANOVA on ranks. The log-rank test was employed for survival analyses. PϽ0.05 was considered significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Nix Synergizes With Gq-Mediated Hypertrophy to Cause Lethal Apoptotic Heart Failure
Nix gene expression increases in human and experimental pressure overload hypertrophy. 15, 17, 24 We previously found that increased expression of Nix alone did not cause functionally significant cardiomyocyte apoptosis in normal adult mice but that Nix caused progressive apoptotic cardiac dilation in neonatal mice 13 and that proapoptotic effects of Nix were inversely proportional to the rate of maturational cardiomyocyte growth. Here, to define possible synergies between Nix and pathological cardiomyocyte growth, 25 we examined the consequences of conditional forced Nix expression in mice with Gq-mediated hypertrophy. Overexpression of Gq is a cardiac myocyte-specific genetic stimulus for pathological hypertrophy that recapitulates many characteristics of compensated pressure overload hypertrophy. 18, 19 As previously observed, 13 cardiac-specific overexpression of Nix beginning in the neonatal period ( Figure 1A ) increased cardiomyocyte apoptosis to levels (Ϸ4%; Figure 1D Figure 1A and 1C, black bars). These results demonstrate that Gq-mediated pathological hypertrophy exacerbates apoptosis caused by Nix overexpression, providing additional evidence for synergy between cardiac growth and death pathways. 25 
Nix Gene Ablation Prevents Gq-Mediated Apoptotic Peripartum Cardiomyopathy
Nix is upregulated in Gq-mediated cardiac hypertrophy, 15, 17 and the aforementioned results show that Gq-mediated hypertrophy contributes to apoptosis caused by Nix expression. A unique manifestation of apoptotic myocardial disease in the Gq mouse is lethal peripartal heart failure. 16, 23 To demonstrate that Nixmediated apoptosis contributes to peripartal heart failure in the Gq mouse, we performed a genetic rescue experiment by crossing Gq transgenic mice to mice lacking a functional Nix gene (Nix null). Germ-line Nix null mice exhibit diminished apoptosis during normal erythroblast maturation 20 Figure 2C and 2D). Crossing ␣-myosin heavy chain-directed Gq transgenic mice with Nix null mice produces a model in which Gq expression is cardiomyocyte specific and Nix ablation is systemic. Thus, cardiac phenotypes reflect the cardiac specificity of the hypertrophy stimulus.
No cardiac effects of parturition or of the peripartum state were observed in Nix null mice (not shown). As observed previously, 16, 23 Gq mice developed peripartal cardiac enlargement and chamber dilation (Figure 2A and LVEDP, LV end-diastolic pressure; and HR, heart rate. E, Transcoarctation gradient in cardiac Nix del mice (nϭ11) and controls (nϭ13). Probability value reported is by t test. MRI indicates magnetic resonance imaging. Peak positive dP/dt (F) and dP/dt at 40 mm Hg (G) LV pressure in cardiac Nix del mice and Nix floxed controls subjected to TAC (nϭ4 per nonoperated group; nϭ11 to 13 per TAC group; probability values reported are by t test for comparison of TAC groups). Nonoperated mice are shown for comparison. H, Change in atrial natriuretic factor (ANF), SERCA2a, and ␣-skeletal (␣Sk) actin mRNA levels 4 days after TAC in WT (white bars) and cardiac Nix del (black bars).
2B) with striking LV remodeling (increase in r/h; Figure  2D ) and a Ͼ50% decline in LV fractional shortening ( Figure 2B and 2C) . Mortality from heart failure in peripartum Gq mice was Ϸ50% (Figure 2E) , and the rate of cardiomyocyte apoptosis (TUNEL positivity) on the first postpartum day was Ϸ8% (Figure 2F Figure 2A and 2B), without remodeling but with significantly improved ejection performance and decreased mortality and cardiomyocyte apoptosis ( Figure 2C through 2F) . These data establish the importance of Nix-mediated apoptosis in the development of, and mortality that results from, apoptotic cardiomyopathy in peripartum Gq overexpressing mice.
Cardiomyocyte-Specific Ablation of Nix Prevents Decompensation of Pressure Overload Hypertrophy
Taken together, the aforementioned results show that Nix is necessary and sufficient for apoptotic decompensation of Gqmediated hypertrophy. To determine whether Nix plays an analogous role in pressure overload hypertrophy (which is also Gq dependent 26, 27 ) in a manner that would not be confounded by extracardiac effects of germ-line Nix ablation, 20 we ablated the Nix gene specifically in cardiomyocytes using Nkx-2.5-driven Cre 21 ( Figure 3A) . Cardiomyocyte-specific Nix KO mice (cardiac Nix del) were viable and exhibited no cardiac abnormalities by gross morphometry or echocardiography (Table 1 and data not shown). Compared with WT control mice, myocardial Nix mRNA levels measured by real-time quantitative polymerase chain reaction were decreased by 78% at baseline in cardiac Nix del mice and showed no change 4 days after imposition of an Ϸ84 mm Hg transaortic gradient by surgical TAC compared with doubling of Nix mRNA after TAC in WT mice ( Figure  3B ). Because Nix mRNA was not detectable with the use of this assay in hearts from germ-line Nix null mice ( Figure 3B ), Nix mRNA at baseline and after TAC in cardiac Nix del hearts likely represents constitutive Nix gene expression in nonmyocyte myocardial cells. 28 -32 Cardiac Nix del and WT mice underwent surgical TAC, 19 producing gradients of 88Ϯ4 and 84Ϯ4 mm Hg, respectively (PϭNS; Figure 3D [top] and 3E). The time courses of hypertrophy development (LV mass), functional decompensation (%FS), and LV remodeling (LV end-diastolic dimension and r/h) were determined by serial echocardiography, followed by terminal invasive hemodynamic studies, cardiac morphometrics, and histological examinations of the myocardium ( Figure 3C ). Gravimetric cardiac hypertrophy measured 9 weeks after TAC, hypertrophy-associated changes in ␣-skeletal actin and sarcoplasmic reticulum ATPase (SERCA2a) gene expression measured 4 days after TAC, and the rate of LV hypertrophy development determined by weekly echocardiography (Table 1 and Figures 3H and 4A ) were identical in cardiac Nix del mice and WT controls, showing that absence of Nix does not affect the hypertrophic response to pressure overload. In contrast, terminal invasive functional assessments of cardiac Nix del mice revealed enhanced myocardial contractile function late after pressure overloading measured as peak positive LV dP/dt or dP/dt at 40 mm Hg LV systolic pressure ( Figure 3D , 3F, and 3G and Table 1 ). Echocardiography confirmed enhanced systolic performance ( Figure 4D to 4F) and further demonstrated that the differences between TAC WT and cardiac Nix del mice in LV diastolic chamber size ( Figure 4B ), remodeling (r/h; Figure 4C ), and systolic performance ( Figure 4D through 4F) were observed by 2 weeks after TAC, with the trend lines remaining roughly parallel thereafter. These findings, together with a significantly smaller increase in failure-associated atrial natriuretic factor mRNA levels ( Figure 3H ), suggest that the benefits of cardiac myocyte Nix ablation on LV remodeling and ejection performance in pressure overloaded hearts largely accrue early after TAC, when apoptosis is most active. To better assess the consequences of cardiomyocytespecific Nix ablation on ventricular remodeling and contractile function after pressure overloading, a cohort of surgically pressure overloaded mice underwent magnetic resonance imaging. 33, 34 Compared with nonoperated controls, magnetic resonance imaging of WT mice 9 weeks after TAC showed increased LV mass and end-diastolic volume, with reduced sphericity index (increased sphericity), and an Ϸ50% decline in volumetric ejection fraction ( Figure 5A and 5B and Table 2 ), representing typical LV remodeling and functional deterioration after acute pressure overloading. 35 In contrast, and consistent with the echocardiographic and invasive hemodynamic findings, pressure overloaded cardiac Nix del mice showed no significant LV dilation and had enhanced LV ejection fraction and a normal LV sphericity index, despite comparable hypertrophy ( Figure  5A and 5B and Table 2 ). These results reinforce the findings of echocardiographic and terminal studies that Nix ablation prevents LV remodeling and minimizes LV functional declines in chronically pressure overloaded hearts.
Cardiomyocyte-Specific Ablation of Nix Diminishes Myocardial Apoptosis in Response to Pressure Overload
Taken together, the aforementioned studies demonstrate that cardiac myocyte-specific Nix ablation largely prevents remodeling and functional deterioration in Gq-mediated and pressure overload hypertrophies. In the Gq model, the benefits of Nix ablation and the deleterious effects of Nix overexpression were associated with reciprocal effects on cardiac myocyte apoptosis. To interrogate the effects of Nix ablation on cardiac myocytes in pressure overload hypertrophy, studies of cardiac myocyte hypertrophy, apoptosis, and replacement fibrosis were performed. Cardiac myocyte cross-sectional area, which is increased in pressure overload hypertrophy, 36 showed similar Ϸ35% increases in WT and cardiac Nix del mice 9 weeks after TAC ( Figure 6A ), indicating that Nix ablation does not affect cellular hypertrophy.
Apoptosis studies in control mice 4 days after TAC showed an Ϸ5-fold increase in the number of TUNEL-positive cardiomyocytes compared with baseline ( Figure 6B ), with increased caspase 3 and PARP cleavage ( Figure 6C ). By comparison, cardiac Nix del hearts after TAC had less TUNEL positivity ( Figure 6B ) and caspase 3 and PARP cleavage ( Figure 6C ). Late fibrotic replacement of dead cardiac myocytes 37 was also reduced by approximately half in cardiac Nix del subjected to TAC compared with identically treated controls ( Figure 6D ). Because provocation of mitochondrial/intrinsic pathway apoptosis is the only known cellular function of Nix, 20 and Nix is specifically upregulated in pressure overload hypertrophy, 15, 24 these results are consistent with the notion that the geometric and functional benefits afforded by cardiomyocyte Nix ablation after pressure overload are a consequence of reduced myocardial apoptotic cell loss.
Discussion
The present studies mechanistically link cardiomyocyte apoptosis with ventricular remodeling and functional deterioration during the transition from compensated pressure overload hypertrophy to decompensated heart failure. They further identify induction of Nix gene expression as a critical molecular event causing apoptotic cardiac myocyte dropout in pressure overload and Gq-mediated hypertrophy. The efficacy of cardiomyocyte salvage by apoptosis inhibition under conditions when no relief is provided from the primary inciting stimulus demonstrates that 
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preventing apoptotic cardiomyocyte death does not simply commit the cell to a necrotic one. We selected Nix as the candidate effector of apoptosis for our studies of hypertrophy decompensation because Nix transcripts are specifically upregulated in pathological hypertrophy. 15, 24 Nix protein rapidly localizes to mitochondrial outer membranes via a carboxyl-terminal hydrophobic localization domain, without which Nix lacks apoptotic activity. 15, 38 Nix protein also undergoes rapid proteolytic degradation, 38, 39 revealing that apoptosis induced by it is tightly regulated by both rapid "start" and "stop" functions. At the mitochondria, Nix promotes the release of cytochrome c by supporting permeabilization of the mitochondrial outer membrane, 20 almost certainly by stimulating oligomerization of the multidomain pore-forming Bcl-2 proteins Bax and Bak. 40 Addition of recombinant Nix to isolated mitochondria does not open permeability transition pores, 20 although this occurs in intact cells undergoing Gq-mediated apoptosis. 23, 41, 42 Thus, available evidence indicates that Nix is a hypertrophy-inducible apical regulator of apoptosis mediated strictly via the intrinsic, mitochondrial pathway. 43 It is notable that Nix ablation in cardiac myocytes and the germ line did not affect the cardiac response to 2 hypertrophic stimuli. Thus, the functional and structural benefits of Nix ablation are independent of the magnitude of the hypertrophic response. This observation is not fully consistent with the proposition that "pathological hypertrophy" is intrinsically harmful, or at least fully dispensable, in pressure overload 44 -46 and suggests that hypertrophy can be tolerated if its deleterious aspects are neutralized. This notion is also consistent with recent studies demonstrating that microischemia due to inadequate angiogenesis contributes to hypertrophy decompensation and that enhancing angiogenesis can prevent this. 6, 47, 48 It is interesting to speculate that microischemia in cardiac hypertrophy may actually contribute to hypertrophic Nix gene induction because hypoxia has been shown to increase Nix transcripts in cultured tumor cell lines, 49, 50 and in the present studies Nix overexpression alone was not sufficient to cause apoptotic heart failure, whereas the same level of Nix expression in the context of Gq-mediated hypertrophy proved lethal.
Why was hypertrophy-associated apoptosis incompletely suppressed by Nix ablation? First, Nix may not be the only mitochondrial apoptotic factor induced in cardiac hypertrophy. We and others have shown that closely related Bnip3 is strongly induced in cardiomyocyte ischemia. 24, 51, 52 Bnip3 and Nix have nearly identical apoptotic effects in cells 38 and may interact cooperatively in the heart (G.W.D. and A.D., unpublished data). Recent evidence that failure of angiogenesis contributes to functional hypertrophy decompensation 6, 47, 53 suggests that cardiomyocyte ischemia may be unavoidable in pressure overload hypertrophy. If so, coinduction of hypertrophic and ischemic apoptotic factors may be the rule, and elimination of apoptosis will not be accomplished by targeting a single gene or gene product.
The second likelihood is that extrinsic, death receptor apoptosis pathways contribute to apoptosis after pressure overload. Certainly, loss of the interleukin-6/gp130 cytokine receptor and its cardiomyocyte survival function leads to dramatic apoptotic decompensation after pressure overloading. 12 The proinflammatory/proapoptotic cytokine tumor necrosis factor-␣ also contributes to decompensation of pressure overload hypertrophy. 54 However, although cross talk occurs between mitochondrial and death receptor apoptosis pathways, 55 Nix is not involved. Thus, it is likely that Nix modulates only apoptosis transduced via the intrinsic pathway in decompensating pressure overload hypertrophy but that death receptor pathways can also contribute.
In conclusion, the present results support the proposition that programmed cardiomyocyte death is at a junction between multiple mechanical and molecular factors that contribute to heart failure, and they demonstrate that moderating cardiomyocyte apoptosis can interrupt the cycle of physiological stress leading to myocyte dropout that, in turn, exacerbates the physiological stress. Retention of cardiac myocytes that were programmed to die is a form of myocardial salvage that helps to maintain normal chamber wall thickness and dimension and therefore preserves cardiac ejection performance and hemodynamic homeostasis.
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CLINICAL PERSPECTIVE
Left ventricular hypertrophy after hemodynamic overload tends inexorably to functionally decompensate through the process of ventricular remodeling. Ventricular dilation and diminished ejection performance in remodeled ventricles have been associated with histological changes reflecting "dropout" of cardiac myocytes and their replacement with fibrous tissue. An unanswered question is whether genetically programmed cardiomyocyte death in the form of apoptosis, which is observed in pressure overloaded hearts, contributes mechanistically to progressive remodeling and functional decompensation in cardiac hypertrophy. We previously observed stimulated expression of specific apoptosis genes in hearts undergoing physiological stress and recently found that ablation of the ischemia-regulated proapoptotic gene Bnip3 prevented postinfarction left ventricular remodeling in gene-targeted mice (J Clin Invest. 2007;117:2825-2833). Here, we show that a related proapoptotic factor, Nix, which is strikingly induced in pathological cardiac hypertrophy, contributes to adverse remodeling of pressure overload and genetic cardiac hypertrophies. Using mouse models in which the Nix gene was ablated in either the whole animal or specifically in cardiac myocytes, we show that absence of Nix in the heart prevents Ϸ50% of apoptotic cardiomyocyte cell death in response to pressure overload or genetically stimulated hypertrophy, restrains left ventricular dilation, and preserves contractile function, thereby preventing development of heart failure. These studies demonstrate feasibility for a general therapeutic strategy of "myocardial regeneration in reverse" by targeting specific stress-induced proapoptotic factors. In the case of pressure overload hypertrophy, functional decompensation can be prevented by minimizing apoptotic myocardial loss and the adverse remodeling that it causes by targeting hypertrophy-inducible Nix.
